Levetiracetam (LEV) has rarely been associated with skin rashes. We managed two patients who developed skin rashes following LEV administration. In this communication we report these patients to highlight the occurrence of skin rashes with LEV.
Patients #1:
A 19-year-old woman had secondary generalized seizures for 18 months due to a calcified parietal granuloma. She was treated with phenytoin (PHT) and sodium valproate. PHT was replaced with LEV 500 mg twice daily because of a recurrence of seizures. Having taken LEV for 10 days, she developed a generalized maculopapular itchy rash which spared the mucous membranes. LEV was stopped and she was prescribed oral cetirizine, ranitidine, and clobazam. Sodium valproate was continued. The skin rash improved over the next 5 days, but she had break through seizures. LEV was restarted at a dose of 750 mg twice daily. On day 7 of LEV administration, she again developed a maculopapular rash this time also affecting the mucus membranes. The skin rash involved more than 70% of body surface area. Her Naranjo score was nine, suggesting a definite association between LEV and skin rash. The patient was managed in intensive care and required nasogastric tube feeding. She was given oxygen by face mask and LEV and sodium valproate was stopped. She received intravenous immunoglobulin 200 mg/kg daily for 5 days, topical steroid ointment, artificial tear and levocetirizine 10 mg daily. After 1 month of hospital treatment, her rash had healed sufficiently for her to be discharged. She remained seizure free for next 1 year on clobazam 15 mg twice daily.
The patient was admitted to our hospital because of recurrence of secondary generalized seizures. On examination, she had healed scar marks from her previous rash on face, trunk and extremities ( Fig. 1 ). She was prescribed gabapentin 100 mg once daily which was increased to 300 mg twice daily in addition to clobazam. She has been seizure for last 4 months.
Patient # 2:
A 29-year-old male had been experiencing seizures and diagnosed with idiopathic generalized epilepsy 2 years previously. Seizures usually occurred at night. The patient had a history of febrile seizures. His seizures were controlled with PHT 200 mg daily but 3 months prior to admission he had two seizures in the context of adherence problems. He was prescribed oxcarbazepine 600 mg daily and PHT was increased to 300 mg. Three months later, he developed an urticarial skin rash all over his body. Phenytoin and oxcarbazepine were stopped and he was referred to our hospital. On examination, he had fading skin rash. He was prescribed LEV 500 mg twice daily but on day 9 of LEV administration, he again developed a morbilliform pruritic rash. Levetiracetam was replaced with clobazam 10 mg daily. One month later, he had a generalized tonic clonic seizure for which LEV 1000 mg daily was prescribed by his local physician. On the third day of LEV treatment, he developed an extensive morbilliform rash. His Naranjo score was seven ( Fig. 1E and F) . The patient was managed symptomatically. LEV was replaced with sodium valproate controlled release 400 mg twice daily and clobazam was continued. At 2 months follow-up, there was no recurrence of seizures or rash. recurred on drug challenge and the Naranjo score was suggestive. Antiepileptic drug related skin rashes may occur following PHT, carbamazepine, oxcarbazepine, phenobarbitone, primidone, zonisamide, lamotrigine, and may have cross reactivity despite differences in the chemical structures of these agents [1, 2] . In contrast, valproate, topiramate, gabapentin, tiagabine and LEV, are rarely associated with skin rashes. Only 0.8% of patients newly started on LEV developed a skin rash [1] . To date, only five patients with LEV-associated skin reactions have been reported (Table 1 ) [3] . Idiosyncratic drug reactions can be attributed to several immunologic mechanisms [2] . Drug reactions can be lifethreatening or a source of considerable morbidity. On rechallenge, the rash usually appears within 2 days [2] . In our patients the drug rashes appeared on the third or seventh day of a LEV rechallenge respectively. The pathogenesis of Stevens-Johnson syndrome and toxic epidermal necrolysis is not fully understood but is believed to be immune-mediated because rechallenge with the responsible chemical trigger results in rapid recurrence of fulminant skin reactions. Immune-mediated drug reactions are thought to be doseindependent, but some reports have discussed the possible role of the dose of the offending drug in immune-mediated reactions [2] . If the drug is started in a very low dose and gradually increased, the risk of allergic reaction is reduced, because of desensitization. The relationship between starting dose and titration rate in cutaneous drug reaction is particularly notable with lamotrigine, PHT and carbamazepine [4] . The skin rash following carbamazepine is commoner in Asians compared to Europeans and American patients because of pharmacogenetic susceptibility due to HLA-B*1502 and HLA-A*3101 alleles [2] . The genetic and epigenetic aspects of LEV related skin rash need further evaluation.
Conclusion
LEV potentially causes skin toxicity. Especially when previous possible rashes have been reported with LEV, rechallenge should only be undertaken after consideration of alternative treatments and with great caution.
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